Pfizer Inc. (FRA:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 115.75B |
| Revenue (ttm) | 57.67B |
| Net Income (ttm) | 7.28B |
| Shares Out | n/a |
| EPS (ttm) | 1.28 |
| PE Ratio | 15.91 |
| Forward PE | 8.29 |
| Dividend | 1.55 (7.61%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 2,948 |
| Average Volume | 44,567 |
| Open | 20.34 |
| Previous Close | 20.30 |
| Day's Range | 20.29 - 20.38 |
| 52-Week Range | 18.57 - 28.96 |
| Beta | n/a |
| RSI | 36.41 |
| Earnings Date | Aug 5, 2025 |
About Chimerix
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsNews
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...
Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' July DiviDogs
Nine of the top sixteen Barron's Better Bets 'Safer' dividend dogs are attractively priced, offering dividends from $1K invested exceeding their share price. Analyst projections suggest 18-29% net gai...
Drug Prices To Get 'More Expensive' Under Trump's EU Trade Deal As Pharma Faces Billions In Added Costs: Report
The pharmaceutical industry could face a significant financial hit due to the new trade deal between the U.S. and the European Union (EU), potentially leading to increased drug prices and restricted a...
BenchSci Expands Board of Directors with Appointment of Dr. Mikael Dolsten
Industry Veteran and Former Pfizer Chief Scientific Officer Brings Extensive R&D and Leadership Experience to Advance BenchSci’s Mission of Improving the Speed and Quality of Preclinical R&D TORONTO —...
Celcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast Cancer
Celcuity Inc. (NASDAQ: CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial, which evaluated gedatolisib plus fulve...
Notable healthcare headlines for the week: Pfizer, UnitedHealth, Sarepta and Thermo Fisher in focus
Keep Calm And Keep Buying These Dividends
Dividend investing has lagged growth stocks recently. When combined with sustained headwinds for the sector, it can be tempting to give up on dividend investing and chase the hot stocks instead. I sha...
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills
Imagine this: a hospital conference room, lights low, filled with decision-makers. A sales representative clicks through slides driven by Palantir Technologies’ (NASDAQ: PLTR) Foundry platform, highl...
Pfizer's Comeback Is Underway
16 Ideal 'Safer' Dividend Dogs To Buy From 70 July Graham Value All-Stars (GVAS)
Graham All Star Value (GASV) strategy identifies top dividend 'dogs' offering high yield and fair pricing, using YCharts' large cap value and Ben Graham screens. Analyst projections suggest the top te...
Pfizer, BioNTech win EU backing for updated COVID shot
Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug
Pfizer and 3SBio have completed a licensing agreement that grants the US pharmaceutical giant worldwide rights to sell the Hong Kong-listed firm’s cancer drug, marking the largest deal ever for a sing...
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8. ...
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union | BNTX Stock News
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recomm...
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency's (EMA) Committee for Medici...
Pfizer hit with lawsuits over cancer risk linked to Depo-Provera birth control shot
Pfizer (PFE) stock in focus as company faces lawsuits over its alleged failure to warn about brain tumor risks linked to Depo-Provera birth control shot. Read more here.
Pfizer's ‘Depo-Provera' Increases Risk of Brain Tumours 3.5 Times Compared to Combined Birth Control Pill According to New Study as Litigation Overseen by Levin Papantonio Rises to Over 550 Lawsuits
A study published on 29 June 2025 in international peer reviewed medical journal Expert Opinion on Drug Safety by Frey et al. has found that use of Pfizer's Depo-Provera (DMPA) for more than one year ...
Pfizer Completes Licensing Agreement with 3SBio
Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the development, manufacturing and co...
Pfizer Completes Licensing Agreement with 3SBio
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the develo...
Lightning Round: You've got the best with CrowdStrike, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Pfizer, CrowdStrike, and Lowe's.
Pfizer Nears Major Bottom: A Turning Point for Investors?
Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% in its stock price.